Cost of Illness and Comorbidities in Adults Diagnosed With Attention-Deficit/Hyperactivity Disorder
- 14 April 2011
- journal article
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 13 (2)
- https://doi.org/10.4088/pcc.10m01030
Abstract
This retrospective study assessed the cost of illness and medical and psychiatric comorbidities in adults with attention-deficit/hyperactivity disorder (ADHD) compared with adults without ADHD (matched 1:3) and adults with depression (1:1). Individuals with depression were included as a benchmark against which the burden of ADHD could be measured. Measures of health care and employment-related costs were compared to generate estimates of medical expenditures, workplace absences, and comorbidities in adults with ADHD (using ICD-9-CM codes) who were enrolled in employer-sponsored health plans throughout 2006. Individuals with ADHD (31,752) were matched with 95,256 non-ADHD controls. The majority of individuals with ADHD (n = 29,965) were also matched with an equal number of individuals with a depression diagnosis (using ICD-9-CM codes). In this adult population with ADHD enrolled in an employer-sponsored health plan, medical and psychiatric comorbidities were the primary drivers of health care utilization and cost. Of note, depression was significantly prevalent among those with ADHD compared to matched non-ADHD controls (14% vs 3.2%; P ≤ .0001). Subgroup analysis demonstrated that ADHD patients with depression had a significantly higher number of medical and other psychiatric comorbid illnesses including diabetes, hypertension, asthma, irritable bowel syndrome, bipolar disorder, anxiety, alcohol abuse, and substance abuse compared to those with ADHD alone (P ≤ .0001). Patients with ADHD incurred higher total annual health care expenditures than control subjects ($4,306 vs $2,418); approximately 15% of costs were paid by the patient. The total annual costs associated with productivity losses were also higher (driven by differences in short-term disability costs) in the ADHD group compared with controls ($4,403 vs $4,209). Medical and psychiatric comorbidities were primary drivers of the direct health care cost associated with ADHD in adult patients. The present study demonstrated that the total costs of ADHD among adults are doubled when indirect costs associated with workplace productivity losses are included.Keywords
This publication has 29 references indexed in Scilit:
- The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey InitiativeOccupational and Environmental Medicine, 2008
- Update on adult attention-deficit/hyperactivity disorder.Current Neurology and Neuroscience Reports, 2008
- Health Care Costs of Adults Treated for Attention-Deficit/Hyperactivity Disorder Who Received Alternative Drug TherapiesJournal of Managed Care Pharmacy, 2007
- Long-acting medications for the hyperkinetic disordersEuropean Child & Adolescent Psychiatry, 2006
- The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey ReplicationAmerican Journal of Psychiatry, 2006
- The effect of ADHD on the life of an individual, their family, and community from preschool to adult lifeArchives of Disease in Childhood, 2005
- Unemployment, Job Retention, and Productivity Loss Among Employees With DepressionPsychiatric Services, 2004
- The Economic Burden of Depression in the United StatesThe Journal of Clinical Psychiatry, 2003
- Estimating log models: to transform or not to transform?Journal of Health Economics, 2001
- Long-term Prognosis in Attention-Deficit/Hyperactivity DisorderChild and Adolescent Psychiatric Clinics of North America, 2000